

## Special Issue

# Management of Glioblastomas

### Message from the Guest Editors

Glioblastoma (GBM) is the most common malignant tumor of the central nervous system in adults, and is characterized by rapid progression and poor prognosis. In addition to high mortality, glioblastoma is associated with high morbidity. Symptoms like seizures, headache, and cognitive decline may occur from the earliest stages of the disease, causing a rapid deterioration of independence in activities of daily living. Despite multimodal treatment efforts, the survival rate for patients with glioblastoma has not significantly improved over the last several decades. Current research is aimed at studying new molecular markers that could allow the early identification of GBM, as well as prompt therapeutic and prognostic definition. However, the field still lacks in-depth knowledge on pathological mechanisms underlying tumor growth and invasiveness. Moreover, the 2021 World Health Organization Classification of Central Nervous System tumors has defined new molecular entities, including IDH-mutant grade 4 astrocytoma and IDH-wild type molecularly defined glioblastoma, whose behavior and response to standardized GBM treatments remain to be defined.

### Guest Editors

Dr. Marco Russo

Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS Reggio Emilia, 42121 Emilia, Italy

Dr. Jessica Rossi

1. Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41121 Modena, Italy
2. Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS Reggio Emilia, 42121 Emilia, Italy

### Deadline for manuscript submissions

closed (30 September 2023)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/127534](https://mdpi.com/si/127534)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)